We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
WST Stock Up Nearly 33% YTD: Will the Uptrend Continue in the Rest of 2026?
Read MoreHide Full Article
Key Takeaways
WST climbed nearly 33% YTD after first-quarter revenues jumped 21% and adjusted EPS surged 47%.
West Pharma is benefiting from strong GLP-1 demand, with HVP Components posting 23% organic growth.
West Pharma raised 2026 guidance as biologics growth and Annex 1 regulations support future expansion.
Shares of West Pharmaceutical Services Inc. (WST - Free Report) have staged an impressive comeback in 2026, rising 32.9% year to date. The stock has outpaced the industry’s 30.3% decline and the S&P 500 Index’s 28.2% increase.
The rebound reflects improving investor confidence following a strong first-quarter earnings beat, accelerating demand in high-value injectable drug components and improving growth visibility across biologics and GLP-1 therapies. West Pharma reported first-quarter 2026 revenues of $845 million, up 21% year over year, while adjusted EPS surged 47%.
The strong performance led management to raise full-year guidance. Supported by structural growth in biologics, obesity drugs and injectable therapies, West Pharma appears to be entering a stronger growth cycle, which can extend the current momentum through the remainder of 2026.
WST’s YTD Performance
Image Source: Zacks Investment Research
Factors Supporting the Rally
GLP-1 Drug Demand Continues to Drive High-Value Product Growth: Accelerating demand for GLP-1 therapies used to treat obesity and diabetes remains West Pharma's largest growth catalyst.High-Value Product (HVP) components, which account for nearly half of the company's revenues, delivered 23% organic growth in the first quarter.
Management highlighted that GLP-1 products accounted for 10% of total company sales, with demand supported by broader insurance coverage, reduced drug pricing and new indications. Management believes the adoption of oral GLP-1 therapies is expanding the overall market rather than replacing injectable therapies, supporting long-term growth visibility.
Biologics Business Is Emerging as a Durable Long-Term Growth Engine: Beyond GLP-1, biologics continues to be a major structural growth driver. West Pharma reported 26% organic growth in biologics-related business during the first quarter, benefiting from strong commercial wins and growing adoption of its premium NovaPure packaging solutions.
Biosimilar launches globally are expanding therapy usage and increasing demand for injectable packaging solutions. Management emphasized continued strong customer win rates for new biologic launches, suggesting sustained growth beyond the obesity drug cycle.
Annex 1 Regulatory Transition Creates Multi-Year Demand Tailwind: European Annex 1 sterile manufacturing regulations are creating another powerful growth catalyst. West Pharma reported a 66% year-over-year increase in Annex 1-related projects, with management expecting these initiatives to contribute approximately 200 basis points to 2026 revenues.
Pharmaceutical companies are increasingly converting standard components toward higher-value HVP solutions to meet stricter compliance requirements. This transition is also supporting margin expansion, with adjusted operating margin improving 350 basis points to 21.4% in the first quarter.
Strategic Product Portfolio Expansion Strengthens Future Pipeline: Recent strategic moves further improve West Pharma’s long-term positioning. The company completed the divestiture of SmartDose 3.5mL manufacturing rights to AbbVie Inc. (ABBV - Free Report) .
Following this, management will focus on more scalable delivery platforms like SmartDose 10mL. The $112.5 million from AbbVie, following the SmartDose 3.5mL divesture, will boost WST’ cash position, which may lead to higher investment in its high-value product component business. West Pharma expanded its Dublin manufacturing facility to support high-volume injectable therapies, particularly next-generation GLP-1 treatments. The commercial launch of Synchrony S1 prefillable syringe systems also strengthens exposure to the growing biologics and vaccine delivery markets.
WST’s Growth Drivers
Image Source: westpharma.com
Competition Remains Intense as Baxter and BD Push Innovation Strategies
Competition remains significant from Baxter International Inc. (BAX - Free Report) and Becton Dickinson and Company (BDX - Free Report) , popularly known as BD. Baxter is currently undergoing a turnaround, with Baxter reporting only 3% reported sales growth while facing infusion pump disruptions, manufacturing cost inflation and tariff pressure.
In contrast, BD reported stronger execution, with 2.6% revenue growth and double-digit expansion across biologic drug delivery and advanced monitoring platforms. Compared with Baxter and BD, West Pharma currently demonstrates superior top-line momentum, significantly stronger margin expansion and more direct exposure to high-growth injectable biologics.
While Baxter remains focused on operational recovery and BD continues broad-based innovation expansion, West Pharma’s sharper focus on high-value pharmaceutical packaging gives it a more concentrated growth advantage in 2026. BD and Baxter remain formidable long-term competitors, but West Pharma presently holds stronger growth momentum.
Risks and Challenges Could Moderate Further Upside
Despite strong momentum, risks remain. Rising oil and commodity costs could pressure margins, although management expects mitigation efforts to limit impact. The SmartDose 3.5 divestiture removes a revenue stream that contributed meaningfully in prior periods, creating short-term revenue transition risk.
West Pharma also remains highly dependent on continued injectable GLP-1 demand growth, making it vulnerable if obesity drug adoption slows unexpectedly or oral GLP-1 demand diminishes demand for injections. In addition, increasing competition from Baxter and BD in drug delivery technologies could intensify pricing pressure over time as injectable therapy markets continue expanding globally.
A Glance at WST’s Estimates
The Zacks Consensus Estimate for WST’s 2026 and 2027 earnings per share (EPS) implies year-over-year growth of 18% and 10.5%, respectively, to $8.60 and $9.50. In the past 60 days, the consensus mark for the company's 2026 EPS has risen 10 cents.
Revenues for 2026 are projected to grow 8.4% to $3.33 billion and another 6.4% to $3.54 billion in 2027.
Image Source: Zacks Investment Research
Conclusion
West Pharma’s strong earnings momentum, structural exposure to GLP-1 therapies, biologics expansion and regulatory-driven product upgrades suggest the stock’s 2026 rally is supported by strong fundamental factors. While competitive and cost pressures remain, the company appears well positioned for continued upside through the rest of 2026.
View the Zacks #1 Rank List
Image: Bigstock
WST Stock Up Nearly 33% YTD: Will the Uptrend Continue in the Rest of 2026?
Key Takeaways
Shares of West Pharmaceutical Services Inc. (WST - Free Report) have staged an impressive comeback in 2026, rising 32.9% year to date. The stock has outpaced the industry’s 30.3% decline and the S&P 500 Index’s 28.2% increase.
The rebound reflects improving investor confidence following a strong first-quarter earnings beat, accelerating demand in high-value injectable drug components and improving growth visibility across biologics and GLP-1 therapies. West Pharma reported first-quarter 2026 revenues of $845 million, up 21% year over year, while adjusted EPS surged 47%.
The strong performance led management to raise full-year guidance. Supported by structural growth in biologics, obesity drugs and injectable therapies, West Pharma appears to be entering a stronger growth cycle, which can extend the current momentum through the remainder of 2026.
WST’s YTD Performance
Image Source: Zacks Investment Research
Factors Supporting the Rally
GLP-1 Drug Demand Continues to Drive High-Value Product Growth: Accelerating demand for GLP-1 therapies used to treat obesity and diabetes remains West Pharma's largest growth catalyst.High-Value Product (HVP) components, which account for nearly half of the company's revenues, delivered 23% organic growth in the first quarter.
Management highlighted that GLP-1 products accounted for 10% of total company sales, with demand supported by broader insurance coverage, reduced drug pricing and new indications. Management believes the adoption of oral GLP-1 therapies is expanding the overall market rather than replacing injectable therapies, supporting long-term growth visibility.
Biologics Business Is Emerging as a Durable Long-Term Growth Engine: Beyond GLP-1, biologics continues to be a major structural growth driver. West Pharma reported 26% organic growth in biologics-related business during the first quarter, benefiting from strong commercial wins and growing adoption of its premium NovaPure packaging solutions.
Biosimilar launches globally are expanding therapy usage and increasing demand for injectable packaging solutions. Management emphasized continued strong customer win rates for new biologic launches, suggesting sustained growth beyond the obesity drug cycle.
Annex 1 Regulatory Transition Creates Multi-Year Demand Tailwind: European Annex 1 sterile manufacturing regulations are creating another powerful growth catalyst. West Pharma reported a 66% year-over-year increase in Annex 1-related projects, with management expecting these initiatives to contribute approximately 200 basis points to 2026 revenues.
Pharmaceutical companies are increasingly converting standard components toward higher-value HVP solutions to meet stricter compliance requirements. This transition is also supporting margin expansion, with adjusted operating margin improving 350 basis points to 21.4% in the first quarter.
Strategic Product Portfolio Expansion Strengthens Future Pipeline: Recent strategic moves further improve West Pharma’s long-term positioning. The company completed the divestiture of SmartDose 3.5mL manufacturing rights to AbbVie Inc. (ABBV - Free Report) .
Following this, management will focus on more scalable delivery platforms like SmartDose 10mL. The $112.5 million from AbbVie, following the SmartDose 3.5mL divesture, will boost WST’ cash position, which may lead to higher investment in its high-value product component business. West Pharma expanded its Dublin manufacturing facility to support high-volume injectable therapies, particularly next-generation GLP-1 treatments. The commercial launch of Synchrony S1 prefillable syringe systems also strengthens exposure to the growing biologics and vaccine delivery markets.
WST’s Growth Drivers
Image Source: westpharma.com
Competition Remains Intense as Baxter and BD Push Innovation Strategies
Competition remains significant from Baxter International Inc. (BAX - Free Report) and Becton Dickinson and Company (BDX - Free Report) , popularly known as BD. Baxter is currently undergoing a turnaround, with Baxter reporting only 3% reported sales growth while facing infusion pump disruptions, manufacturing cost inflation and tariff pressure.
In contrast, BD reported stronger execution, with 2.6% revenue growth and double-digit expansion across biologic drug delivery and advanced monitoring platforms. Compared with Baxter and BD, West Pharma currently demonstrates superior top-line momentum, significantly stronger margin expansion and more direct exposure to high-growth injectable biologics.
While Baxter remains focused on operational recovery and BD continues broad-based innovation expansion, West Pharma’s sharper focus on high-value pharmaceutical packaging gives it a more concentrated growth advantage in 2026. BD and Baxter remain formidable long-term competitors, but West Pharma presently holds stronger growth momentum.
Risks and Challenges Could Moderate Further Upside
Despite strong momentum, risks remain. Rising oil and commodity costs could pressure margins, although management expects mitigation efforts to limit impact. The SmartDose 3.5 divestiture removes a revenue stream that contributed meaningfully in prior periods, creating short-term revenue transition risk.
West Pharma also remains highly dependent on continued injectable GLP-1 demand growth, making it vulnerable if obesity drug adoption slows unexpectedly or oral GLP-1 demand diminishes demand for injections. In addition, increasing competition from Baxter and BD in drug delivery technologies could intensify pricing pressure over time as injectable therapy markets continue expanding globally.
A Glance at WST’s Estimates
The Zacks Consensus Estimate for WST’s 2026 and 2027 earnings per share (EPS) implies year-over-year growth of 18% and 10.5%, respectively, to $8.60 and $9.50. In the past 60 days, the consensus mark for the company's 2026 EPS has risen 10 cents.
Revenues for 2026 are projected to grow 8.4% to $3.33 billion and another 6.4% to $3.54 billion in 2027.
Image Source: Zacks Investment Research
Conclusion
West Pharma’s strong earnings momentum, structural exposure to GLP-1 therapies, biologics expansion and regulatory-driven product upgrades suggest the stock’s 2026 rally is supported by strong fundamental factors. While competitive and cost pressures remain, the company appears well positioned for continued upside through the rest of 2026.
WST currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.